IPCALAB — Ipca Laboratories Income Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedLarge CapHigh Flyer

Annual income statement for Ipca Laboratories, fiscal year end - March 31st, INR millions except per share, conversion factor applied.

	2022 March 31st	2023 March 31st	2024 March 31st	2025 March 31st	2026 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	PRESS
Standards:	IAS	IAS	IAS	IAS	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	58,298	62,443	77,050	89,396	96,463
Cost of Revenue
Gross Profit	34,487	35,130	46,027	56,151	68,236
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	47,714	55,448	69,495	78,473	81,900
Operating Profit	10,584	6,996	7,556	10,923	14,564
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	11,146	7,453	8,427	11,311	15,725
Provision for Income Taxes
Net Income After Taxes	8,898	4,919	5,292	7,875	11,914
Minority Interest
Equity in Affiliates
Net Income Before Extraordinary Items
Net Income	8,841	4,713	5,474	7,377	11,411
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	8,841	4,713	5,474	7,377	11,411
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	35.2	18.2	25.9	36.2	47.6
Dividends per Share